AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04779853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for pertussis antibody testing
Description: Blood samples will be sent to the laboratories of the National Centers of Expertise within 24-48 hours of blood collection. The samples will be transferred to the reference laboratory of SPCSEEM in Almaty, Kazakhstan. Serum samples will be stored in the reference laboratory at a temperature of -20 C.
Study NCT05088421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BWC0977
Description: SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
Study NCT05088421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
Study NCT06094166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Quantitative imaging MR parameters
Study NCT04566172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: Participants will receive an inspiratory muscle training that they will do leading up to the day of their surgery.
Study NCT06342700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib crystalline form
Description: Pharmaceutical form:Film coated tablet Route of administration:Oral
Study NCT06342700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilzabrutinib amorphous form
Description: Pharmaceutical form:Film coated tablet Route of administration:Oral
Study NCT05378464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
Study NCT05378464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pepinemab
Description: Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
Study NCT05378464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cell therapy
Description: Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
Study NCT06473961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes
Description: A tumor sample is resected from each participant and cultured ex vivo to generate tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC101 TIL followed low-dose PD-1 antibody.
Study NCT05917067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescence imaging of the parathyroid glands of children
Description: Patients that participate in this study will always receive standard care. For the purpose of this study, the camera settings (i.e. camera distance to the operating field, switching of OR-lights, and angle of the camera on the operating field) and ICG-protocol (i.e. dose, injection speed) will be standardized among the participating centers in order to generate an homogeneous data set for quantification of the fluorescence signal intensity.
Study NCT05401487 — intervention group
Intervention type: OTHER
Intervention: Pre-hospital and hospital care
Description: Pre-hospital care not exceeding 60 min and a whole body CT scan within 45 min for patients categorized as unstable or critical by the pre-hospital doctor and 90 minutes for patients deemed potentially serious.
Study NCT05323474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual rehabilitation
Description: Usual rehabilitation according to the practice of the Haute Autorité de Santé (HAS)
Study NCT05323474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation optimized
Description: Rehabilitation optimized according to the study protocol
Study NCT06537999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNTH103
Description: * Day 1: IV loading dose~* Week 1 to Week 15: DNTH103 administered SC every 2 weeks
Study NCT06537999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Day 1: IV infusion of placebo~* Week 1 to Week 15: placebo administered SC every 2 weeks
Study NCT05774002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aims to Decrease Anxiety and Pain Treatment (ADAPT)
Description: One pre-operative and 4 post-operative sessions of cognitive behavioral therapy (CBT) treatment in the first two months, beginning 2-3 weeks after surgery, will be completed.
Study NCT04936230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine and blood sample collection
Study NCT04936230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT04936230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04936230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04936230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04936230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT04936230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04936230 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT06430021 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 8 mL blood sample in EDTA tube
Study NCT00733200 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Minor or Major Liver Resection
Study NCT06668805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide Injection
Description: Modified recombinant human C-type natriuretic peptide Vosoritide
Study NCT06668805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Growth Hormone
Description: Commercial product containing somatotropin.
Study NCT06132282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance Use and Health Risk Intervention (SUHRI)
Description: Technology-based intervention designed as 4 sessions administered on a tablet as a self-directed approach (requiring an onsite proctor) for addressing factors that increase risk for significant health problems. Topics such as SU and risky sex are important but often sensitive or difficult for juvenile justice staff to address in their role as probation officers.
Study NCT06611319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevention of Venous Thromboembolism
Description: Direct oral anticoagulant
Study NCT06611319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevention of Venous Thromboembolism
Description: Direct oral anticoagulant
Study NCT06611319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT06672081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Catheter-Interventional Treatment
Description: Patients will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these.Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation.
Study NCT06672081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional care
Description: reperfusion treatment
Study NCT06672081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: reperfusion treatment
Study NCT06591026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Helpline (SH)
Description: One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.
Study NCT06591026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Helpline (SH)
Description: One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.
Study NCT06591026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: One digital helpline session that includes a structured motivational interviewing brief intervention.
Study NCT05475483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM3355 capsules
Description: Treatment will be blind for the whole duration of the study.
Study NCT05475483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Treatment will be blind for the whole duration of the study.
Study NCT06040918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: fixed dose of 1 mg by subcutaneous (SC) injection
Study NCT06162663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant Tablets
Description: Suvorexant initially with 10-20 mg for 28 days
Study NCT06162663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Matched Placebo Control for 28 days
Study NCT04545723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FibriCheck
Description: FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
Study NCT04628169 — intervention group
Intervention type: OTHER
Intervention: no intervention applied
Description: no intervention applied
Study NCT05609877 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline will be administered intravenously instead of pre-procedure analgesia.
Study NCT05609877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Less Invasive Surfactant Administration (LISA)
Description: All infants will be treated with the Less Invasive Surfactant Administration (LISA) procedure
Study NCT05609877 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Less Invasive Surfactant Administration (LISA)
Description: All infants will be treated with the Less Invasive Surfactant Administration (LISA) procedure
Study NCT05609877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 0.5-1.0 mcg/kg will be administered intravenously as pre-procedure analgesia
Study NCT05609877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-pharmacological standard operating procedure
Description: All infants will receive the same non-pharmacological standard operating procedure.
Study NCT05609877 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non-pharmacological standard operating procedure
Description: All infants will receive the same non-pharmacological standard operating procedure.
Study NCT06044909 — intervention group
Intervention type: PROCEDURE
Intervention: Minimal invasive hepatectomy, intraoperative stage
Description: Trocar layout is recorded by photo or diagram. The video of conventional or robot-assisted laparoscopy and intraoperative laparoscopic ultrasound images (where applicable) are recorded by the surgeon and anonymized. Depth measurements of internal structures (tumors, cysts, vascular network, anatomical landmarks) are taken using identifiable points on the surface of the liver for tumour resection.
Study NCT06044909 — intervention group
Intervention type: PROCEDURE
Intervention: Minimal invasive hepatectomy, postoperative stage
Description: The registration of imaging data in conventional or robot-assisted laparoscopy is performed by the scientific team using the developed registration algorithm. The data obtained from the clinical intervention will help improve the registration algorithm.
Study NCT06044909 — intervention group
Intervention type: OTHER
Intervention: Preoperative data collection
Description: Patient code (anonymised) + inclusion number, repeated on each page. Anonymised CT or MRI scan and date of scan. Type of cancer, planned surgery and approach (robotic or laparoscopic). Patient's age. Patient's surgical history. Toxic habits: tobacco, alcohol. Healthy liver, liver disease, cirrhosis. Anticoagulant and antiaggregant treatment.
Study NCT06044909 — intervention group
Intervention type: OTHER
Intervention: Intraoperative data collection
Description: Endoscope calibration. Intraoperative surgical and ultrasound images. Measurements for tumor's size and tumor's distances from liver surface and vascular vascular structures.
Study NCT06044909 — intervention group
Intervention type: OTHER
Intervention: Postoperative data collection
Description: Definitive anatomical pathology with the measurement of resection margins.
Study NCT05275608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VLCKD diet with replacing meals
Description: Patients will receive an accurate teaching + brochure on VLCKD diet from an expert dietician and freely receive the correct amount of supplements provided from Labotaoire Therascience (4 or 5 meals). The supplements contain (in total) between 600 and 800 kcal, mainly fats, 1,2/1,5 g/body weight of proteins, very low amount of charbohydrates (\<30/40g/die), 10-20g fibers, + minerals and vitamins covering the needings of patients. After 6-8 weeks, 1 meal will be replaced with a natural dish rich in proteins.
Study NCT05275608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric mediterranean Diet
Description: Patients will receive an accurate teaching + brochure on an hypocaloric Mediterranean style diet (LARN 2014) from an expert dietician. Patients will follow the istructions on grams and foods to eat. The calories will be around minus 400-500 kcal from energy requirement (measured by indirect calorimetry \* physical activity score).
Study NCT06177197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiomer
Description: Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant > 6 months: one single dose administered per nostril 6 times a day.
Study NCT06177197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant > 6 months: one single dose administered per nostril 6 times a day.
Study NCT06377696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive SOC
Study NCT06377696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear wearable device
Study NCT06377696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear wearable device
Study NCT06377696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Given PO
Study NCT06377696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Assessment
Description: Undergo neurocognitive test
Study NCT06377696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Assessment
Description: Undergo neurocognitive test
Study NCT06377696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06377696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05557851 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
Study NCT05551000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental, comparator and control
Description: To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group.
Study NCT05551000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental, comparator and control
Description: To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group.
Study NCT05138822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: GSK3882347 will be administered on each dosing day.
Study NCT05138822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin will be administered on each dosing day.
Study NCT05138822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
Study NCT05138822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
Study NCT05345015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Energy Transfer
Description: Radiofrequency Electrical Currents (TECAR) will be delivered using a winback system (Winback, Villeneuve-Loubet, France) propagating radiofrequency waves of 448 kHz using metallic electrodes via a coupling medium. Radiofrequencies will be used in the capacitive mode , which aims to treat superficial /soft tissues in the area. The active plate will be applied sequentially on the skin in the injured or painful region. The base plate will be located to the other side of the injured body region (for back thigh muscle injuries, for example, the base plate will be located on the frontal thigh area, to close the current circuit. Therapy will be applied for 20 minutes, with a target intensity of 40% and a frequency of 0.5Mhz.
Study NCT05345015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulation
Description: Transcutaneous nerve stimulation (TENS) will be delivered using a Chattanooga Intellect Advanced Combo system (Chattanooga, Hixson, TN 3 7343, USA). Two electrodes will be placed on the skin at a distance so that they cover the entire painful area. The TENS asymmetric biphasic mode (phase 300 ms, frequency 80Hz, continuous cycle) will be applied. The intensity will be adjusted between 0 and 110A, such that it is tolerable by the participant. The total application time will be 20 minutes or equal to that applied for the TECAR group.
Study NCT05561127 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GIE Medical ProTractX3 TTS DCB
Description: The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter.
Study NCT05561127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of Care Endoscopic Dilation
Study NCT06236165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Patients will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.
Study NCT06236165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.
Study NCT05758376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Bridge
Description: Recovery Bridge is a Peer Specialist facilitated intervention designed to help Veterans being discharged from an inpatient psychiatric hospitalization bridge the gap to outpatient care and community living
Study NCT05937438 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Immune Checkpoint Inhibitors
Description: Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year